The effect of oral and injectable anticoagulant drugs on bleeding rate in patients undergoing gynecological oncological surgeries

Document Type : Original Article

Authors

1 Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

2 Resident, Department of Obstetrics and Gynecology, Clinical Research Developmental Unit, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Abstract

Introduction: Women's cancers such as endometrium, ovary, cervix, and vulva are common and one of the most effective treatments is the use of surgical techniques. Today, the use of injectable anticoagulants (heparin and enoxaparin) before and after women's cancer surgeries is common in treatment protocols. The present study was performed with aim to compare the effect of oral (apixaban) and injectable (enoxaparin) anticoagulant drugs in patients undergoing gynecological oncological surgeries.
Methods: This clinical trial study was carried out from 2021 to 2022 on 80 women referred to the hospital of Iran University of Medical Sciences with the complication of women's cancer (ovary, uterus, cervix, vulva and vagina, etc.) whose disease was confirmed by diagnostic laboratory evaluations and specialist physician and were diagnosed for surgery. After discharge, all patients used two treatment protocols of oral anticoagulants or injectable drugs within 28 days. Demographic information and laboratory indices of patients were evaluated. Data analysis was done using SPSS statistical software (version 22) and Mann-Whitney test. P<0.05 was considered significant.
Results: There was no significant difference between the groups receiving oral and injectable anticoagulants in terms of bleeding time and hospitalization duration (p>0.05). Also, the amount of hemoglobin and platelets in both groups decreased after surgery compared to before surgery, which was statistically significant (p<0.05).
Conclusion: The use of oral and injectable anticoagulants has no effect on the amount of bleeding after surgery in patients with gynecological cancers.

Keywords

Main Subjects

References

  1. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 2011; 365(11):981-92.
  2. Hoffman MS, Chi DS, Clarke-Pearson DL, Cliby W, Creasman W, Underwood Jr PB. Surgical training in gynecologic oncology: past, present, future. Gynecologic oncology 2020; 158(1):188-93.
  3. Cokkinides V, Albano J, Samuels A, Ward M, Thum J. American cancer society: Cancer facts and figures. Atlanta: American Cancer Society; 2005.
  4. Kumar A, Bakkum-Gamez JN, Weaver AL, McGree ME, Cliby WA. Impact of obesity on surgical and oncologic outcomes in ovarian cancer. Gynecologic oncology 2014; 135(1):19-24.
  5. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ. Executive summary: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141(2):7S-47S.
  6. Padbury C, Harris M, LaCouture M, Spyropoulos J. Success of online CME at improving knowledge and confidence around guideline-directed management of cancer-associated thrombosis. Blood 2020; 136:13.
  7. Guntupalli SR, Brennecke A, Behbakht K, Tayebnejad A, Breed CA, Babayan LM, et al. Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial. JAMA network open 2020; 3(6):e207410-.
  8. Zhou H, Ye LL, Zhou JT, Ma FX, Ma JJ, Zhang JH. Direct oral anticoagulants (DOACs) versus low-molecular-weight heparin (LMWH) for extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: a systematic review and meta-analysis. Surgical Endoscopy 2024: 1-8.
  9. Shimizu T, Iwama N, Tokunaga H, Endo S, Miyahara S, Toki A, et al. Precautions during Direct Oral Anticoagulant Introduction in Gynecologic Malignancies: A Single-Center Retrospective Cohort Study. Cancers 2023; 15(4):1132.
  10. Longo de Oliveira ALM, de Oliveira Pereira RF, Agati LB, Ribeiro CM, Kawamura Suguiura GY, Cioni CH, et al. Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial : Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial). Clin Appl Thromb Hemost 2022; 28:10760296221132556.
  11. Carter J, Rowland K, Chi D, Brown C, Abu-Rustum N, Castiel M, et al. Gynecologic cancer treatment and the impact of cancer-related infertility. Gynecologic oncology 2005; 97(1):90-5.
  12. Ushijima K. Current status of gynecologic cancer in Japan. Journal of gynecologic oncology 2009;20(2):67-71.
  13. Yamagami W, Nagase S, Takahashi F, Ino K, Hachisuga T, Aoki D, et al. Clinical statistics of gynecologic cancers in Japan. Journal of gynecologic oncology 2017; 28(2).
  14. Akyüz A, Güvenç G, Üstünsöz A, Kaya T. Living with gynecologic cancer: experience of women and their partners. Journal of nursing scholarship 2008; 40(3):241-7.
  15. Konno Y, Todo Y, Minobe S, Kato H, Okamoto K, Sudo S, et al. A retrospective analysis of postoperative complications with or without para-aortic lymphadenectomy in endometrial cancer. International Journal of Gynecologic Cancer 2011; 21(2).
  16. Baruah U, Begum D, Barmon D, Aparajita. Superior Vena Cava Syndrome: An Occurrence of Surprise in Gynecological Cancer. Indian Journal of Gynecologic Oncology 2022; 20(4):59.
  17. De Crem N, Peerlinck K, Vanassche T, Vanheule K, Debaveye B, Middeldorp S, et al. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thrombosis research 2015; 136(4):749-53.
  18. Gressel GM, Marcus JZ, Mullen MM, Sinno AK. Direct oral anticoagulant use in gynecologic oncology: a Society of Gynecologic Oncology clinical practice statement. Gynecologic oncology 2021; 160(1):312-21.
  19. Signorelli JR, Gandhi AS. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: a pilot study. Journal of Oncology Pharmacy Practice 2019; 25(2):362-8.
  20. Mahmoud MS. Oral Dabigatran versus Enoxaparin for Thromboprophylaxis after Gynecological Procedure. International Journal of Basic and Applied Sciences 2017; 6(4):163-167.
  21. Zhang J, Xu F, Zhang Z, Sang C, Wu A. Prophylactics for lower-extremity deep venous thrombosis in high-risk patients after gynecologic surgery: a prospective study. Int J Clin Exp Med 2018; 11(8):8223-31.
  22. Mistry DA, Chandratreya A, Lee PY. A systematic review on the use of aspirin in the prevention of deep vein thrombosis in major elective lower limb orthopedic surgery: an update from the past 3 years. The Surgery Journal 2017; 3(04):e191-6.
The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 26, Issue 12
February 2024
Pages 1-10

Files

Share

How to cite

Statistics